CME paper: Elderly patients at risk for coronary heart disease or stroke: Selecting an ideal product for lipid lowering

American Journal of Geriatric Cardiology

Volumn 10, Issue 2, 2001, Pages 77-84

  Rackley, C E ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SIMVASTATIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

AGE; ANGINA PECTORIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG CHOICE; DRUG MECHANISM; DRUG SAFETY; ELDERLY CARE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; VASCULAR ENDOTHELIUM; VASODILATATION; AGED; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; MIDDLE AGED;

AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED;

EID: 0035099503     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2001.00838.x     Document Type: Review

References (45)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol And Recurrent Events (CARE) trial
7. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The Cardiovascular Health Study
8. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years
9. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol And Recurrent Events (CARE) study
10. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study
11. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials
12. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
13. Vascular effects of stains in stroke
14. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points
15. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
16. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
17. Role of endothelium in ischemic coronary syndromes
18. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
19. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
20. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
21. Prospective study of markers of hemostatic function with risk of ischemic stroke
22. Effect of statins on C-reactive protein in patients with coronary artery disease
23. Long-term effects of pravastatin on plasma concentration of C-reactive protein
24. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
25. Platelet-dependent thrombin generation in patients with hyperlipidemia
26. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
27. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
28. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia
29. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
30. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
31. Effects of lovastatin therapy on plasminogen activator inhibitor 1 antigen levels
32. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
33. The design of a prospective study of pravastatin in the elderly at risk
34. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
35. Polypharmacy in the elderly: A fait accompli?
36. Use of prescription medications in an elderly rural population: The MoVIES Project
37. Cardiovascular pharmacology of aging
38. Natural statins and stroke risk
39. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
40. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
41. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
42. Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin
43. Drug-related morbidity and mortality: A cost-of-illness model
44. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile